Farms.com Home   News

O&T Farms says $10M plant expansion will grow grain market in Sask.

Oleet Processing and its parent company O&T Farms announced a $10 million expansion at their plant northwest of Regina. The company says it will translate into new jobs and a bigger grain market for Saskatchewan farmers.

O&T is already Canada’s largest processor of flaxseed, buying 50,000 metric tonnes of flaxseed, canola, pulses and alfalfa each year. The expansion – which will also add a new warehouse, maintenance facility and office – means the plant will have the ability to process an estimated 130,000 metric tonnes annually, which is used in products for animal health and performance, pet food, methane reduction, and omega-3 foods for humans.

According to O&T, 80 per cent of the grain it buys comes from Saskatchewan farms.

“This gives farmers a much-needed larger local market thereby reducing their reliance on exporting raw, unprocessed grain to countries such as China,” the company explained in a statement. “This is important for building a consistent, stable and profitable flax market for prairie farmers.”

The plant currently sustains 262 jobs, the company noted, with about 20 new jobs coming after the expansion, with a tripling of the associated economic activity.

Tim Wiens, president of O&T Farms and Oleet Processing, said the company is seeing global demand increasing.

“We are pioneers and world leaders in producing natural, plant-based Omega-3 fatty acids products that help livestock and consumers alike,” Wiens said in a statement.

“We see demand increasing, and our market expanding, which is why we are confident in doubling our Saskatchewan manufacturing capacity.”

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.